Taxane anticancer agents: a patent perspective

Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study

(2017) V. Dieras et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent.

(2017) M. Beeram et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas.

(2017) S. A. Jeyapalan et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

(2017) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate–taxoid conjugate

(2015) Joshua D. Seitz et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer

(2015) R. de Leeuw et al.   CLINICAL CANCER RESEARCH

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

(2015) Madduri Srinivasarao et al.   NATURE REVIEWS DRUG DISCOVERY

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

(2014) J. Baselga et al.   ANNALS OF ONCOLOGY

Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis

(2014) K. Kubota et al.   ANNALS OF ONCOLOGY

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

(2014) Rastislav Bahleda et al.   INVESTIGATIONAL NEW DRUGS

Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery

(2014) Vladimir P. Torchilin   NATURE REVIEWS DRUG DISCOVERY

The synthesis of novel taxoids for oral administration

(2013) Yun-rong Jing et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer

(2013) Paul L. McCormack   DRUGS

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

(2013) Cora N. Sternberg et al.   ONCOLOGY

Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic

(2012) Iontcho R. Vlahov et al.   BIOCONJUGATE CHEMISTRY

A critical review of lipid-based nanoparticles for taxane delivery

(2012) Lan Feng et al.   CANCER LETTERS

Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?

(2012) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Liposomal paclitaxel formulations

(2012) Štěpán Koudelka et al.   JOURNAL OF CONTROLLED RELEASE

Synthesis and biological evaluation of novel 3′-difluorovinyl taxoids

(2012) Larissa Kuznetsova et al.   JOURNAL OF FLUORINE CHEMISTRY

Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer

(2011) Thomas Dipetrillo et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

(2011) M. S. Darshan et al.   CANCER RESEARCH

Tumor-targeting drug delivery of new-generation taxoids

(2011) Iwao Ojima et al.   Future Medicinal Chemistry

Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes

(2011) Berta Otová et al.   INVESTIGATIONAL NEW DRUGS

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

(2011) Beth Y. Karlan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma

(2010) A. Y. Bedikian et al.   ANNALS OF ONCOLOGY

Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug Release

(2010) Shuyi Chen et al.   BIOCONJUGATE CHEMISTRY

Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study

(2010) Nicholas Robert et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer

(2010) Alison K. Conlin et al.   Clinical Breast Cancer

In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells

(2010) P. Ulivi et al.   CURRENT CANCER DRUG TARGETS

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells

(2010) Galina I Botchkina et al.   Molecular Cancer

Cabazitaxel

(2010) Matthew D. Galsky et al.   NATURE REVIEWS DRUG DISCOVERY

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer

(2009) Francisco Robert et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

(2009) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Larotaxel: broadening the road with new taxanes

(2009) Otto Metzger-Filho et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Transport characteristics of a novel peptide platform for CNS therapeutics

(2009) Yanick Bertrand et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Recent Advances in the Chemistry and Biology of New Generation Taxoids‡

(2009) Iwao Ojima et al.   JOURNAL OF NATURAL PRODUCTS

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

(2008) X. Pivot et al.   ANNALS OF ONCOLOGY

A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors

(2008) Qian Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

(2008) L Paz-Ares et al.   BRITISH JOURNAL OF CANCER

In Reply

(2008) Tomasz M. Beer   JOURNAL OF CLINICAL ONCOLOGY

Design, Synthesis, and Biological Evaluation of New-Generation Taxoids

(2008) Iwao Ojima et al.   JOURNAL OF MEDICINAL CHEMISTRY

Functionalized Single-Walled Carbon Nanotubes as Rationally Designed Vehicles for Tumor-Targeted Drug Delivery

(2008) Jingyi Chen et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY